TiGenix 'remarkable' early stem cell success in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Belgian firm TiGenix has unveiled positive early Phase IIa data for its allogeneic stem cell product, Cx611, in refractory rheumatoid arthritis which it belives are "remarkable in that they constitute the first ever signal of clinical activity of a cell therapy in RA". But this did not translate to any hike in the firm's share price, which on 22 April opened 3% higher at €0.92 compared with the previous day's close but in the end closed at a disappointing €0.80.